Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 16, 2022; 10(35): 13122-13128
Published online Dec 16, 2022. doi: 10.12998/wjcc.v10.i35.13122
Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report
Cai Xu, Deng-Gui Luo, Zhe-Yan Liu, Dong Yang, Dan-Dan Wang, Yuan-Zhao Xu, Jun Yang, Bo Fu, Ai-Rong Qi
Cai Xu, Deng-Gui Luo, Zhe-Yan Liu, Dong Yang, Yuan-Zhao Xu, Jun Yang, Bo Fu, Ai-Rong Qi, Department of Nephrology, The Fourth Affiliated Hospital of Guangzhou University of Chinese Medicine, Shenzhen 518000, Guangdong Province, China
Dan-Dan Wang, Department of Nephrology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518000, Guangdong Province, China
Author contributions: Xu C and Luo DG contributed equally to this work; all authors have read and approve the final manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ai-Rong Qi, PhD, Chief Physician, Department of Nephrology, The Fourth Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 1 Fuhua Road, Futian District, Shenzhen 518000, Guangdong Province, China. 81863418@163.com
Received: October 11, 2022
Peer-review started: October 11, 2022
First decision: November 2, 2022
Revised: November 10, 2022
Accepted: November 24, 2022
Article in press: November 24, 2022
Published online: December 16, 2022
Processing time: 64 Days and 5.1 Hours
Core Tip

Core Tip: Anemia of dialysis-dependent chronic kidney disease is commonly treated with erythropoiesis-stimulating agents (ESAs), along with iron supplementation; however, in some cases, patients cannot be administered erythropoiesis-stimulating agents. Roxadustat is a newly developed drug for renal anemia treatment. It is an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. In this study, we presented a case in which Roxadustat was administered for the treatment of a patient allergic to ESAs. This was the first case where roxadustat was administered to improve anemia in a patient allergic to ESAs and on maintenance hemodialysis.